Transforming Scientific Discoveries into Medicines

Some of the greatest innovations in medicine have originated in academic laboratories—modalities and therapies that have transformed patient care. But for every promising new approach that moves to the clinic, many more remain latent, waiting to be identified or resourced. Autobahn Labs is a new model in the acceleration of early-stage drug discovery and development. In partnering with academic institutions and scientists, we help to identify the most promising early-stage research projects that can spark the development of meaningful new therapies for patients.

Autobahn Labs was created by Samsara BioCapital, a leader in life sciences investments, and Evotec, a global leader in drug discovery and development research, and KCK Ltd., a family investment fund investing in scientifically and technically challenging projects. Our long-term investment philosophy combined with our world-class drug discovery and development capabilities enable us to accelerate the translation of scientific ideas to novel therapeutics.

Our Vision

Catalyze the translation of innovative science into transformational new therapies

Why Autobahn Labs?

Vested partnerships with academic institutions and scientists

Deep operational expertise provided by industry experts, 3,000+ scientists

Industrialized drug discovery capabilities

Long-term capital and committed investors

Established drug discovery framework with track record of advancing discovery and preclinical research

Our Model

Autobahn Labs works with principal investigators and tech transfer offices to identify areas of novel science for collaboration. We provide seed funding to move projects from target validation, hit identification and preclinical toxicology studies, to the nomination of a preclinical drug candidate.